Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Rectal Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

Rituximab 19zanubrutinib 13acalabrutinib 11Magnetic Resonance Spectroscopy 11obinutuzumab 10Specimen Handling 10Cyclophosphamide 10Biopsy 9glofitamab 8Bendamustine Hydrochloride 8pirtobrutinib 7fludarabine 7venetoclax 6orelabrutinib 6Lenalidomide 5Cytarabine 5ibrutinib 4fludarabine phosphate 3Immunotherapy, Adoptive 3CT-P10 3tafasitamab 2polatuzumab vedotin 2loncastuximab tesirine 2brexucabtagene autoleucel 2Whole-Body Irradiation 2Therapeutics 2Prednisone 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Mantle-Cell × Endoscopy, Gastrointestinal × Clear all
NCT06839053 2026-04-22

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡